# Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Source: https://onco.cc/trials/nct07435038/  
OnCo record `nct07435038` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in pancreatic cancer, run by Betta Pharmaceuticals Co., Ltd., now recruiting.

## Summary

Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS is a phase 1/2, interventional study registered as NCT07435038 by Betta Pharmaceuticals Co., Ltd., with a registry enrolment figure of 120 participants, started 2026-01-29 and due to reach its primary completion in 2028-12-28. Interventions recorded: BPI-572270. Conditions listed: Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Advanced Solid Tumors. Primary outcome: DLT; RP2D; ORR. Sites: Australia, China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07435038
- Phase: 1/2
- Setting: A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS.
- Sponsor: Betta Pharmaceuticals Co., Ltd.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT07435038: https://clinicaltrials.gov/study/NCT07435038

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07435038.json